Genome-wide association studies (GWASs) and the role of the SARM1-negative regulator Stathmin-2 (SCG10) (Shin et al., 2012) in amyotrophic lateral sclerosis (ALS) also implicate programmed axon degeneration in human disease (Fogh et al., 2014; Klim et al., 2019; Melamed et al., 2019; van Rheenen et al., 2016). This evidence concerns the gene STMN2 and amyotrophic lateral sclerosis.